Unibest
← Back to patent-cliff list

Avatrombopag Maleate

Tier C — Watch / trade

Avatrombopag Maleate · all drugs expiring in 2030 →

Astellas Pharma Inc.
Originator
2018
First approval
2030
Expiry (public)
$0.58B ▲
Peak sales
Small molecule
Type

Targets:TpoR

Brand:Doptelet, DOPTELET

Indications (approved):Thrombocytopenia, Immune thrombocytopenic purpura, Liver disease

Regional status

US
Approved
2018-05-21
EU
Approved
2019-06-20
China
Approved
2020-04-14
Japan
Approved
2023-03-27

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Sign in to view factories →

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 7 · Total yield 20 kg
Synthetic routes & intermediates Route 1
CodeCAS No.Intermediate
AVAT-00134730-20-6Available1-(4-chlorothiophen-2-yl)ethanone
AVAT-002677007-73-7Available2-bromo-1-(4-chlorothiophen-2-yl)ethanone
AVAT-00362-56-6Availablethiourea
AVAT-004570407-10-2Available4-(4-chlorothiophen-2-yl)thiazol-2-amine
AVAT-00517766-28-8Available1-cyclohexylpiperazine
AVAT-006570407-42-0Available4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-amine
AVAT-00741667-95-2Available5,6-dichloronicotinic acid
AVAT-008570403-04-2Available5,6-dichloro-N-(4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)nicotinamide
AVAT-0091126-09-6Availableethyl piperidine-4-carboxylate
AVAT-010570403-14-4Availableethyl 1-(3-chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylate
AVAT-011110-16-7Availablemaleic acid

Frequently asked questions

What are the approved indications of Avatrombopag Maleate?

Approved indications include: Thrombocytopenia, Immune thrombocytopenic purpura, Liver disease.

When does the Avatrombopag Maleate patent expire?

Based on public sources, the Avatrombopag Maleate patent expires in 2030.

How many synthesis routes are recorded for Avatrombopag Maleate?

1 synthesis routes are recorded; the shortest is 7 steps with 20 kg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Avatrombopag Maleate intermediates?

11 intermediate CAS of Avatrombopag Maleate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Avatrombopag Maleate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29